STL Index for: Vimal H. Prajapati
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Explore the groundbreaking role of Spesolimab, a novel interleukin-36 inhibitor, in treating Generalized Pustular Psoriasis flares in adults. This article presents key findings from phase 1 and 2 clinical trials, emphasizing Spesolimab's effectiveness and safety.
Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults
Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.
Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.
Advances in Pemphigus Therapy
The pemphigus variants represent a group of potentially life-threatening autoimmune mucocutaneous blistering diseases. Herein, we focus on the new and emerging therapies in the management of pemphigus.
Rituximab: A B-Cell Depletion Therapy for Dermatologic Disease
Rituximab (Rituxan®, Genentech/ Biogen Idec) is a genetically engineered chimeric murine/human monoclonal antibody directed against CD20. While anecdotal case reports recommend its “off-label” use in dermatology, randomized clinical trials are required to firmly establish the safety and efficacy.
